Penbraya is a pentavalent conjugate vaccine developed by Pfizer for the prevention of invasive meningococcal disease in people 10 through 25 years of age.[1] Invasive meningococcal disease, caused by the bacterium Neisseria meningitidis, can lead to serious conditions such as meningitis (inflammation of the brain and spinal cord lining) and sepsis.[2] Penbraya is approved for use by the US Food and Drug Administration (FDA).[3] Penbraya is the first pentavalent vaccine that provides coverage against the five most common serogroups causing meningococcal disease.[4]
Composition
Penbraya is a vaccine that combines components of two previously licensed meningococcal vaccines: